SCHEMBL1726817

SCHEMBL1726817

CC(C)(C)c1ccc2c(c1)CCC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.43
ALDH1A1 P00352 5/20 0.41
HPGD P15428 2/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
KIF11 P52732 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 3/20 0.39
DHODH Q02127 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
MLNR O43193 1/20 0.39
HTT P42858 1/20 0.39
RAPGEF4 Q8WZA2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10627376 0.95 TRPV1 (0.47) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL11767095 0.89 KIF11 (0.43) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL6903925 0.84 ALDH1A1 (0.43) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL6900356 0.84 ALDH1A1 (0.43) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL24305261 0.83 CA12 (0.41) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL4579825 0.83 ALDH1A1 (0.42) TRPV1ALDH1A1CA12CA1CA2
SCHEMBL10203278 0.83 ALDH1A1 (0.41) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL19398844 0.81 DRD1 (0.47) ALDH1A1HPGDALOX15SMN1; SMN2
SCHEMBL16603454 0.81 MLNR (0.56) MLNR
SCHEMBL18408971 0.79 NPC1 (0.42) ALDH1A1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0192492-B1 PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1992-01-02 EP claimed
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 US disclosed
US-20230285340-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-09-14 US disclosed
US-11547687-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-01-10 US disclosed
US-11518744-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-12-06 US disclosed
US-20210079017-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-18 US disclosed
US-20210059966-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-04 US disclosed
US-20210047270-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2021-02-18 US disclosed
US-10759813-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-09-01 US disclosed
US-10744104-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-08-18 US disclosed
US-9555041-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-01-31 US disclosed
US-20170020904-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-01-26 US disclosed
US-20170022219-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-01-26 US disclosed
EP-2403846-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. Hoffmann-La Roche AG (CH) 2012-01-11 EP disclosed
WO-2010100070-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2010-09-10 WO disclosed
EP-1658269-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR Abbott Laboratories (US) 2006-05-24 EP disclosed
WO-2004111009-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LABORATORIES (US) 2004-12-23 WO disclosed
EP-0192492-B1 PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1992-01-02 EP disclosed
US-4677193-A GONADOTROPIN-RELEASING FACTOR ANALOGS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1987-06-30 US disclosed
EP-0192492-A2 Peptides containing an aliphatic-aromatic ketone side chain THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1986-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285340-A1 NEPRILYSIN INHIBITORS MME, REN, ACE TRPV1 1341/4885ALDH1A1 2945/4885HPGD 3244/4885
US-10759813-B2 Neprilysin inhibitors MME, REN, ACE TRPV1 1733/4885ALDH1A1 2644/4885HPGD 2701/4885
US-20170022219-A1 NEPRILYSIN INHIBITORS MME, REN, ACE TRPV1 1733/4885ALDH1A1 2644/4885HPGD 2701/4885
US-11547687-B2 Neprilysin inhibitors MME, REN, ACE TRPV1 1341/4885ALDH1A1 2945/4885HPGD 3244/4885
US-20170020904-A1 NEPRILYSIN INHIBITORS MME, REN, ACE TRPV1 1943/4885ALDH1A1 3385/4885HPGD 3232/4885
US-10744104-B2 Neprilysin inhibitors MME, REN, ACE TRPV1 1341/4885ALDH1A1 2945/4885HPGD 3244/4885
US-20210079017-A1 NEPRILYSIN INHIBITORS MME, REN, ACE TRPV1 1733/4885ALDH1A1 2644/4885HPGD 2701/4885
US-20210059966-A1 NEPRILYSIN INHIBITORS MME, REN, ACE TRPV1 1341/4885ALDH1A1 2945/4885HPGD 3244/4885
US-20210047270-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF JAK2, STAT3, STAT5A TRPV1 164/4885ALDH1A1 635/4885HPGD 2264/4885
US-12016835-B2 Neprilysin inhibitors MME, REN, ACE TRPV1 1341/4885ALDH1A1 2945/4885HPGD 3244/4885
US-11518744-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof JAK2, STAT3, STAT5A TRPV1 164/4885ALDH1A1 635/4885HPGD 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.